Celldex Capital Surpluse from 2010 to 2024

CLDX Stock  USD 26.58  0.36  1.37%   
Celldex Therapeutics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 1 B in 2024. During the period from 2010 to 2024, Celldex Therapeutics Capital Surpluse regression line of annual values had r-squared of  0.81 and arithmetic mean of  970,259,195. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
1.6 B
Current Value
1.6 B
Quarterly Volatility
398.3 M
 
Yuan Drop
 
Covid
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Celldex Therapeutics over the last few years. It is Celldex Therapeutics' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Celldex Capital Surpluse Regression Statistics

Arithmetic Mean970,259,195
Geometric Mean839,914,777
Coefficient Of Variation48.13
Mean Deviation359,768,556
Median1,016,128,630
Standard Deviation466,986,507
Sample Variance218076.4T
Range1.5B
R-Value0.90
Mean Square Error44679T
R-Squared0.81
Slope93,965,076
Total Sum of Squares3053069.6T

Celldex Capital Surpluse History

2024B
20231.8 B
20211.6 B
20201.3 B
20191.1 B
20181.1 B
2017B

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse1.8 BB

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.